MorphoSys Appoints Head of Clinical Development

17-Sep-2009 - Germany

MorphoSys AG announced the appointment of Lisa Rojkjaer, MD, as Vice President and Head of Clinical Development.

Dr. Rojkjaer joins MorphoSys from Novartis Pharma AG where she most recently held the position of Head of Medical Affairs - Hematology, Europe, following her appointment as global clinical program head for Exjade®. Here she was responsible for all clinical activities in Europe for Novartis's Hematology portfolio including Gleevec® and Exjade®. Prior to her tenure at Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, USA as the Director of Global Medical Affairs Biopharmaceuticals and later Director, Clinical Development Hematology. During her time with Novo Nordisk she established a global medical affairs group for biopharmaceuticals and headed the clinical development of the US hematology portfolio amongst other accomplishments. Dr. Rojkjaer is a board certified hematologist and received her MD degree from the University of Toronto, where she also did her residency in internal medicine and fellowship in hematology. She has held academic and hospital appointments in the US, Canada and Europe.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances